Novartis' Gilenia Extension Trial Data Support Efficacy Of Low-Dose Version
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
New data on Novartis' investigational oral multiple sclerosis therapy Gilenia (fingolimod) strengthened the efficacy profile of the low dose 0.5 mg version of the drug and highlighted potential benefits of switching from Biogen Idec's Avonex (interferon beta-1a)